This study aims to improve outcomes for patients with NCI High Risk B-Cell Acute Lymphoblastic Leukemia (B-ALL) and patients with NCI Standard Risk B-ALL with high risk features. High risk features are when the leukemia has spread to the spinal fluid or testes, or one received steroid treatment before being diagnosed with leukemia.
   

This clinical trial is for men and women with newly diagnosed or relapsed/refractory acute myeloid leukemia.

The purpose of this study is to determine a safe dose of an investigational new drug (ziftomenib) in combination with other study drugs i.e., venetoclax and azacitidine or cytarabine plus daunorubicin. This will include an evaluation of side effects associated with ziftomenib in combination with the other study drugs and also aims to determine how ziftomenib works in combination with the other study drugs.

This clinical trial is for adult participants who have pancreatic ductal adenocarcinoma or colorectal cancer with a specific type of mutation (mKRAS or mNRAS) present in their cancer. 

The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that “target” those changes. This combination of a tumor with a mutation and a drug that aims at that mutation is called a “match.” There are two steps for participants in this study.
   

The purpose of this study is to test the safety of the anti-cancer immunotherapy drug called nivolumab in patients with cancer and autoimmune disorders. This study is part of a larger study that looks at several different autoimmune disorders including Systemic lupus erythematosus, Dermatomyositis/systemic sclerosis, Multiple sclerosis, Rheumatoid arthritis, Ulcerative colitis, Crohn's disease, Sjogren's syndrome, Psoriasis, Psoriatic arthritis or other autoimmune diseases not specified. 
   

The purpose of this research study is to determine whether the investigational product, AVB-114, is safe and effective to treat perianal fistulas in people with Crohn’s disease.

This is a pilot study of single dose of 225Ac-J591 at 90 KBq/Kg in men with progressive metastatic castration resistant prostate cancer (mCRPC).

The study will test an investigational product called VCN-01 in patients with metastatic pancreatic cancer. “Investigational” means that VCN-01 has not been approved by the U.S. Food and Drug Administration (FDA) to treat any disease.

This study is evaluating the drugs nab-paclitaxel and gemcitabine in combination with avutometinib (VS-6766) and defactinib for patients with pancreatic ductal adenocarcinoma.

The purpose of the study is to better understand if, how and to what extent art therapy may help patients receiving treatment for cancer or hematology illnesses. This is an observational study and does not involve any interventions.